Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin
Language English Country United States Media print
Document type Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
17176756
DOI
10.1007/bf02931580
Knihovny.cz E-resources
- MeSH
- Acetamides pharmacology MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Biofilms drug effects growth & development MeSH
- Drug Therapy, Combination MeSH
- Microscopy, Confocal MeSH
- Humans MeSH
- Linezolid MeSH
- Lysostaphin pharmacology MeSH
- Microbial Sensitivity Tests MeSH
- Oxacillin pharmacology MeSH
- Oxazolidinones pharmacology MeSH
- Staphylococcal Infections drug therapy MeSH
- Staphylococcus aureus drug effects MeSH
- Vancomycin pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Evaluation Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Acetamides MeSH
- Anti-Bacterial Agents MeSH
- Linezolid MeSH
- Lysostaphin MeSH
- Oxacillin MeSH
- Oxazolidinones MeSH
- Vancomycin MeSH
Due to high resistance, standard chemotherapy of biofilm-associated staphylococcal infections is ineffective and a number of alternative approaches to antimicrobial treatment have been proposed. Minimum inhibitory concentration (MIC) and biofilm inhibitory concentration (BIC) of oxacillin (Oxa), vancomycin (Van), linezolid (Lzd) and lysostaphin (Lss) as well as the possible synergistic effect of the antibiotics and lysostaphin were determined. The Lss susceptibility of Staphylococcus aureus planktonic and bio-film cultures varied and was strain-dependent. The synergistic effect of sub-BIC(Lss)+Oxa was observed for methicillin-sensitive S. aureus (MSSa) and methicillin-resistant S. aureus (MrSa), but not for heterogeneously vancomycin-resistant S. aureus (V(h)Sa) biofilm. Van with sub-BICL(Lss) was effective against M(s)Sa and MrSa biofilm, when applied in three subsequent doses. Only sub-BICL(Lss)+Lzd combination, given as three cycles therapy, was effective in disruption of all 3 (M(s)Sa, M(r)Sa, V(h)Sa) biofilms.
See more in PubMed
J Antimicrob Chemother. 2001 Nov;48(5):617-25 PubMed
Pol J Microbiol. 2005;54(3):191-200 PubMed
Folia Microbiol (Praha). 2004;49(1):75-8 PubMed
Mol Microbiol. 2002 Mar;43(6):1367-78 PubMed
Antimicrob Agents Chemother. 2002 Feb;46(2):598-9 PubMed
Antimicrob Agents Chemother. 2001 Apr;45(4):999-1007 PubMed
Folia Microbiol (Praha). 2004;49(5):596-600 PubMed
Antimicrob Agents Chemother. 2001 May;45(5):1431-7 PubMed
J Antimicrob Chemother. 2003 May;51 Suppl 2:ii27-35 PubMed
J Microbiol Methods. 2003 Aug;54(2):269-76 PubMed
Antimicrob Agents Chemother. 2003 Nov;47(11):3407-14 PubMed
Vaccine. 1999 May 14;17 (19):2423-8 PubMed
J Antimicrob Chemother. 2002 Feb;49(2):301-8 PubMed
Antimicrob Agents Chemother. 2002 Jun;46(6):2017-20 PubMed
Nat Rev Microbiol. 2004 Feb;2(2):95-108 PubMed
Expert Rev Anti Infect Ther. 2003 Dec;1(4):667-83 PubMed
Invest Ophthalmol Vis Sci. 2002 Dec;43(12):3712-6 PubMed
Ann Clin Microbiol Antimicrob. 2005 Jan 07;4:2 PubMed
Antimicrob Agents Chemother. 2004 May;48(5):1681-7 PubMed
In vitro effects on biofilm viability and antibacterial and antiadherent activities of silymarin
Bacteria competing with the adhesion and biofilm formation by Staphylococcus aureus
Antibiotic synergy against biofilm-forming Pseudomonas aeruginosa
Staphylococcus cohnii hemolysins - isolation, purification and properties
Characteristics of Staphylococcus aureus isolated from rabbits
Ribotyping and biotyping of Staphylococcus epidermidis isolated from hospital environment
Treatment of orthopedic infections caused by resistant staphylococci
